• Pediatric Infection and Vaccine
• /
• 제21권2호
• /
• pp.81-95
• /
• 2014

목적: 조혈모세포이식 환자들은 b 형 헤모필루스 인플루엔자(Haemophilus influenzae type b, Hib)과 폐렴구균(Streptococcus pneumoniae, Sp)에 의한 침습성 감염에 취약하다. 방법: 삼성서울병원에서 2009-2011년 사이에 조혈모세포 이식 환자들에게 Hib와 Sp 백신을 접종하고 면역반응을 평가하였다. 결과: 10명의 소아환자가 참가하였고 연령의 중앙값은 5.5세 이었다. Hib 백신 이전에는 60%의 환자에서 anti-PRP IgG가 측정 하한값 $0.15{\mu}g/mL$ 보다 낮았으나 접종 후 100%의 환자에서 $0.15{\mu}g/mL$와 방어 항체가 $1.0{\mu}g/mL$ 이상으로 증가하였다. Sp 백신을 접종한 2-5세 환자 군은 접종 전 6개의 혈청형에 대한 기하 평균 항체가가 $0.35{\mu}g/mL$ 미만이었으나 접종 후 5개월째 7개 혈청형에 대한 기하 평균 항체가가 모두 $0.35{\mu}g/mL$ 이상으로 증가하였다. 5세 초과의 환자 군에서는 접종 전에 4개의 혈청형에 대한 기하평균 항체가가 $0.35{\mu}g/mL$ 미만이었으나 접종 후 3개월째 검사한 7개 혈청형에 대한 기하 평균 항체가가 모두 $0.35{\mu}g/mL$ 이상 증가하였다. 결론: 소아조혈모세포 이식 환자에서 Hib와 Sp 백신접종 후 면역 반응을 보임을 관찰하였다. 국내 소아 조혈모세포 이식 환자에서 이들 백신에 대한 면역반응 연구가 지속적으로 필요할 것으로 사료된다.

• 대한두경부종양학회지
• /
• 제16권2호
• /
• pp.228-234
• /
• 2000

Objectives: Esthesioneuroblastoma is a rare malignant neoplasm that originates from the olfactory sensory cells. This tumor grows from the upper nasal cavity and ethmoid sinus and invades surrounding structures through the cribriform plate into intracranium or orbit in advanced stage. Even though there has been some controversies in determining standard treatment due to rarity of this tumor, the combination treatment of surgery and adjuvant radiation has been recommended for the locally advanced esthesioneuroblastomas. However, the recent clinical experiences of advanced cases showed that combination chemotherapy is highly effective to reduce tumor mass and improve clinical outcomes. Materials and Methods: The authors conducted a retrospective analysis of 6 esthesioneuroblastoma patients who were treated in our hospital from 1986. Results: The age of these patients was between 19 and 86 year-old. Among the 6 cases, 2 were diagnosed at stage B and 4 at stage C, according to Kadish classification. Anti-tumor treatments were performed in 5 patients. One patient refused active treatment and was lost to follow-up. Better survival outcome were observed in 3 patients who were treated with combination chemotherapy alone or combined modality treatment including chemotherapy. Conclusion: Based on our retrospective study, the combined treatment consisting of surgery, radiotherapy, and combination chemotherapy should be used to improve treatment results. And furthermore, innovative clinical approaches such as neoadjuvant chemotherapy, high-dose chemotherapy and autologous peripheral stem cell transplantation, which have been reported to have good therapeutic results, should be considered and applied actively.